Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Fig. 2

Overall survival (OS) estimates by (a) Heng prognostic score, (b) the duration of prior anti—VEGF inhibitors ≥6 months, and (c) pretherapy NLR. The median follow---up times are (a) 19.7 (10.9,NR) months for ‘Low’ and 18.9 (14.7, 41.8) months for ‘Int/High’, (b) 19.7 (18.4,61.2) months for ‘VEGF6 = 0’ and 14.7 (12.7,NR) months for ‘VEGF6 ≥ 1’, and (c) 19.7 (16.1,61.2) months for ‘NLR < 3’ and 18.4 (12.0,NR) months for ‘NLR ≥ 3’

Back to article page